Trial · NCT03341156
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Amount of Chest Tube Drainage | From patient out of room time until 24 hours after | Primary outcome: Amount of chest tube output in the first 24 hours |
| Secondary | Postoperative INR | 30 Minutes post-treatment (after the last dose is completed) | INR value |
| Secondary | INR Value Less Than 1.5 | 30min Post-Protamine | 30 min after the administration of study drug (Kcentra or FFP) |
| Secondary | Hemostatic Blood Products | In OR (from OR entry to OR out of room time); postoperatively (patient out of room time) to 24 hours after; from 24 hours after until 30 days post surgery or until discharge (whichever comes first) | Total hemostatic blood product use, including plasma, platelets, and cryoprecipitate. |
| Secondary | Red Blood Cell Use | Intraoperatively(from start of first intervention until start of second intervention;after 2nd intervention(post-bypass)until patient out of room time) & Postoperatively(from patient out of room time until 24 hours after;24 hours after until 30 days) | Red Blood Cell Use Intraoperatively and Postoperatively |
| Secondary | Need for Circulatory Support | 30 days post-operative or until discharge (whichever comes first) | Percentage of patients who needed circulatory support (ECMO or VAD) |
| Secondary | Mechanical Ventilation | 30 days post-operative or until discharge (whichever comes first) | Percentage of patients who needed mechanical ventilation for more than 72 hours |
| Secondary | Tracheostomy | 30 days post-operative or until discharge (whichever comes first) | Percentage of patients who needed a tracheostomy |
| Secondary | Renal Failure | 30 days post-operative or until discharge (whichever comes first) | Percentage of patients who experience renal failure requiring dialysis |
| Secondary | Sepsis | 30 days post-operative or until discharge (whichever comes first) | Percentage of patients who experienced sepsis infection morbidity consisted of sepsis syndrome, septic shock, or mediastinitis. In addition, the diagnosis of sepsis included organisms isolated from the cultures along with elevated temperature and white blood cell counts. |
| Secondary | Death | 30 days post-operative or until discharge (whichever comes first) | Percentage of patients who died |
| Secondary | Stroke or Postoperative Neurological Dysfunction | 30 days post-operative or until discharge (whichever comes first) | Percentage of patients who experienced a stroke or postoperative neurological dysfunction (seizures, delirium, unconsciousness, encephalopathy) |
| Secondary | Gastrointestinal Complication Requiring Bowel Resection | 30 days post-operative or until discharge (whichever comes first) | Percentage of patients who experienced gastrointestinal complications requiring bowel resection |
| Secondary | Peripheral Vascular Complication | 30 days post-operative or until discharge (whichever comes first) | Percentage of patients who experience peripheral vascular complications requiring surgery (thrombectomy, bypass, and amputations) |
| Secondary | Deep Vein Thrombosis and Pulmonary Thromboembolism | 30 days post-operative or until discharge (whichever comes first) | Percentage of patients who develop a deep vein thrombosis and/ or pulmonary thromboembolism |
| Secondary | Plasma Coagulation Factor Levels | At baseline, post-bypass/pre-protamine, 30 minutes post-protamine, 12-24 hours post treatment | Plasma coagulator factor levels will be analyzed via blood laboratory tests |
| Secondary | Thrombin Generation Assay | At baseline, post-bypass/pre-protamine, 30 minutes post-protamine, 12-24 hours post treatment | Thrombin Generation assay will be analyzed via blood laboratory tests |
| Secondary | Surgical Re-exploration | 30 days post-operative or until discharge (whichever comes first) | Surgical Re-Exploration that is related to heart transplant surgery |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03341156/registered